TRDA:NASDAQ, Entrada Therapeutics, Inc.
TRDA stock overview
Entrada Therapeutics, Inc. (TRDA:NASDAQ) closed at $4.64 on November 19, 2026,
down 7.75% on the day.
The stock trades 71.8% below its 52-week high of $16.45
and 12.9% above its 52-week low of $4.11.
Over the past year, it lost 45.1%.
Entrada Therapeutics, Inc. is part of the Health Care sector.
Key figures
- Price
- $4.64
- Day change
- -7.75%
- Volume
- 324,345
- Average volume
- 396,493
- Market cap
- 181M+
- 52-week range
- $4.11 – $16.45
- 50-day average
- $5.46
- 200-day average
- $8.36
Price action over the past year
In 252 trading sessions since November 18, 2025, TRDA closed higher on 125 days (50%).
Its best day was November 2, 2026 (+12.68%) and its worst was May 7, 2026 (-57.27%).
The stock moved 10% or more in a single session 9 times.
Recent signals
TRDA news
-
Nov 18, 2026:
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Increased Dose of 15 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study
-
Nov 5, 2026:
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates
-
Nov 5, 2026:
Entrada Therapeutics Reports Third Quarter 2026 Financial Results
-
Oct 21, 2026:
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
-
Oct 14, 2026:
What's Going On With Entrada Therapeutics Stock Wednesday?
-
Oct 14, 2026:
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
-
Oct 14, 2026:
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study
-
Sep 10, 2026:
Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program
About Entrada Therapeutics, Inc.
Entrada Therapeutics Inc mission is to transform the treatment of devastating diseases and improve patients quality of life by developing intracellular biologics. Leveraging its proprietary Endosomal Escape Vehicle platform, Entrada is creating a diverse and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to efficiently target and engage underlying drivers of diseases.
Similar stocks
Find more stocks like TRDA with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.